Biosimilars are not small molecule generic drugs and therefore generic-like commercial dynamics should not be expected in the biosimilar market: that's the crux of Johnson & Johnson's justification for tough contract negotiations with payers for Remicade (infliximab), which rival Pfizer Inc. says have unfairly blocked its biosimilar Inflectra (infliximab-dyyb).
J&J's Janssen Biotech Immunology President Scott White talked with Scrip Oct. 11 about the commercial dynamics in the infliximab market...




